تم رفع سعر هدف جابل إنك.

What happened: Argus, a financial analyst firm, raised its target price for Jabil Inc. (JBL) to $475 on June 18, 2026, marking a significant increase from its previous target of $300 set in March 2026. This revision comes amidst positive developments in the EMS industry and Jabil's performance. Additionally, shares of Advanced Energy Industries (AEIS) and CytomX Therapeutics (CTMX) crossed their respective analyst target prices of $93.25 and $16, indicating potential upside for these stocks.

Market impact: The positive target price revisions for JBL, AEIS, and CTMX signal a bullish sentiment in the EMS and healthcare sectors. This could drive investment flows into these companies and their peers, potentially leading to broader sector-wide gains. The revisions also suggest that analysts expect these companies to outperform their respective benchmarks, which could lead to valuation repricing and increased trading activity.

What to watch next: Investors should closely monitor Jabil's upcoming earnings release scheduled for August 4, 2026, to assess the company's performance and guidance. Additionally, any updates on CytomX's Phase 1 data for its lead asset Varseta-M could provide further catalysts for the stock. Lastly, investors should keep an eye on the broader EMS industry trends and any regulatory changes that may impact these companies.